checkAd
    Startseite > Aktien > OKYO Pharma > Nachrichten
    OKYO Pharma Aktie
    0,0137
     
    USD
    0,00 %
    0,0000 USD
    Letzter Kurs 13.05.23 Nasdaq OTC
    ISIN: GG00BD3FV870 · WKN: A2JQ3D · SYM: EMMLF · Guernsey

    Neueste Nachrichten

    OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
    30.04.24 · globenewswire · OKYO Pharma
    OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
    09.04.24 · globenewswire · OKYO Pharma
    OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
    02.04.24 · globenewswire · OKYO Pharma
    OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
    22.03.24 · globenewswire · OKYO Pharma
    OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
    21.03.24 · globenewswire · OKYO Pharma
    OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
    20.03.24 · globenewswire · OKYO Pharma
    OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
    09.02.24 · globenewswire · OKYO Pharma
    OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
    31.01.24 · globenewswire · OKYO Pharma
    OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
    08.01.24 · globenewswire · OKYO Pharma
    OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
    05.01.24 · globenewswire · OKYO Pharma
    OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction
    31.10.23 · globenewswire · OKYO Pharma
    OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
    09.10.23 · globenewswire · OKYO Pharma